In a notable development in the global healthcare sector, the hospital-acquired infections (HAI) therapeutics market was valued at USD 12.5 billion in 2023. Exhibiting a promising compound annual growth rate (CAGR) of 3.2% from 2024 to 2032, the industry expansion is significantly bolstered by a rise in HAIs. Factors such as prolonged hospital stays, increased hospital admissions, and growing usage of invasive devices are catalyzing market growth.
An upsurge in healthcare-acquired infections, a marked emphasis on enhanced patient care, and active governmental participation in curbing these infections are essential drivers behind this robust market progression. Prevalent HAI forms including pneumonia, urinary tract infections, and bloodstream infections provide an impetus for research institutions and pharmaceutical companies to find potent therapeutic interventions.
The rising number of immunocompromised patients is yet another reason for the escalating HAI incidences. Addressing this complex issue, the pharmaceutical industry is channeling funds into the R&D of new and effective antimicrobial therapies. Through this, they hope to combat the threat of antibiotic resistant strains, a concern looming over the HAI therapeutics market.
Moreover, advanced therapeutics, tailor-made for specific pathogens and infection types, are improving patient health outcomes and propelling the industry forward. A key trend shaping the industry is the adoption of rapid diagnostic tests and molecular diagnostics for the swift identification of pathogens, resulting in accurate and effective treatment plans.
Market segmentation based on the drug type classifies products into antibacterial drugs, antifungal drugs, antiviral drugs, and other drug types, with the antibacterials generating the highest revenue of USD 9.2 billion in 2023. Routes of administration categorize the market into intravenous (IV), oral, topical, and inhalation, with IV forms generating market-leading revenue of USD 5.7 billion in 2023.
The market is further segmented based on infection types, including surgical site infections, bloodstream infections, urinary tract infections, and ventilator-associated pneumonia among others. In 2023, the highest revenue of USD 5.2 billion originated from the surgical site infections segment.
Regionally, the North American market accounted for USD 4.7 billion in revenue in 2023 and projects a CAGR of 2.5% between 2024 to 2032. The U.S. market represented a major chunk of this revenue at USD 4.3 billion, and expectations are high for significant growth between 2024 and 2032.
An exponential growth is also forecasted for the U.K HAI therapeutics market in upcoming years. Asia Pacific’s market dominance rests with Japan. Key players in the industry include Pfizer, Merck & Co., and GlaxoSmithKline, and they are relentlessly working on developing new antimicrobial agents for HAIs. The industry is also marked by new antibiotic approvals and expanded research programs tackling multi-drug resistant pathogens.
Source: https://www.gminsights.com/industry-analysis/hospital-acquired-infections-therapeutics-market